ALK and neuroblastoma: Crizotinib, a first-generation ALK inhibitor approved for ALK-translocated lung tumors, was less effective in preclinical neuroblastoma models, especially in tumors harboring the neuroblastoma-associated ALK-F1174L mutation which showed innate resistance to this therapy (12–14).